Emergent BioSolutions develops and manufactures medical countermeasures and specialty biologics aimed at public-health threats, including vaccines and treatments historically linked to anthrax, smallpox and other government-priority pathogens. A substantial share of demand comes from government stockpiling and preparedness contracts. The company also provides contract development and manufacturing services for other biopharma products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 130.3 | — | -12 | — |
| Q3 2025 | 222 | — | 51.2 | — |
| Q4 2025 | 143.8 | — | -54.6 | — |
| Q1 2026 | 149.7 | — | 6.8 | — |
| Q2 2026 | 226.8 | 74.1% | -180.2 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: CION Investment Corporation (CION), Chain Bridge Bancorp, Inc. (CBNA), High Templar Tech Limited (HTT), DWS Municipal Income Trust (KTF), Jackson Acquisition Company II (JACS), CoastalSouth Bancshares, Inc. (COSO)